Matrix metalloprotease-9 in cerebrospinal fluid correlates with disease activity in lymphomatous meningitis

Clinical Lymphoma and Myeloma

Volumn 7, Issue 4, 2007, Pages 305-308

  Wong, Eric T ^a,b   Lee, Diana ^a,b   Tam, Angela ^a,b   Gautam, Shiva ^a   Wu, Julian K ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Brain; Central nervous system; Neoplastic meningitis

Indexed keywords

CYTARABINE; GELATINASE A; GELATINASE B; GLUCOSE; METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE;

ARTICLE; BRAIN LYMPHOMA; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG MEGADOSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; LONGITUDINAL STUDY; LYMPHOMATOUS MENINGITIS; MENINGITIS; PROTEIN CEREBROSPINAL FLUID LEVEL; ZYMOGRAPHY;

EID: 33947135440     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.007     Document Type: Article

References (17)

1. Glass JP, Melamed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29:1369-1375.
2. Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of biochemical markers. Neurology 1998; 50:1173-1175.
3. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759-772.
4. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82:733-739.
5. Rogers LR, Duchesneau PM, Nunez C, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992; 42:1239-1241.
6. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Neurology 1995; 38:51-57.
7. Rundhaug JE. Matrix metalloproteases, angiogenesis, and cancer. Clin Cancer Res 2003; 9:551-554.
8. Yamamoto M, Mohanam S, Sawaya R, et al. Differential expression of membrane-type matrix metalloprotease and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996; 56:384-392.
9. Van Meter TE, Broaddus WC, Rooprai HK, et al. Induction of membrane-type-1 matrix metalloprotease by epidermal growth factor-mediated signaling in gliomas. Neuro-Oncol 2004; 6:188-199.
10. Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101:139-145.
11. Wong ET, Appignani B, Wu JK, et al. Arterial spin labeling MRI detects early recurrence and anti-angiogenic drug effect in recurrent malignant gliomas. J Clin Oncol 2005; 23:132s (Abstract #1573).
12. Friedberg MH, Glantz MJ, Klempner MS, et al. Specific matrix metalloprotease profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998; 82:923-930.
13. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
14. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000; 54:1670-1675.
15. Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103:481-490.
16. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002; 2:289-300.
17. Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004; 117:1847-1856.